SLNO · As filed with the SEC
Soleno Therapeutics income statement, by fiscal year
The statement as Soleno Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Income (Loss) · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Product revenue, net | 190,405,000 | — | — | — |
| Operating expenses | ||||
| Cost of goods sold | 2,700,000 | — | — | — |
| Research and development | 40,627,000 | 78,568,000 | 25,189,000 | 15,265,000 |
| Selling, general and administrative | 132,128,000 | — | — | — |
| General and administrative | — | 105,861,000 | 13,481,000 | 9,844,000 |
| Change in fair value of contingent consideration | 5,536,000 | 3,242,000 | 2,714,000 | (712,000) |
| Total operating expenses | — | 187,671,000 | 41,384,000 | 24,397,000 |
| Total operating expenses | 180,991,000 | — | — | — |
| Operating income (loss) | 9,414,000 | (187,671,000) | (41,384,000) | (24,397,000) |
| Other income (expense), net | ||||
| Change in fair value of warrant liability | 0 | 0 | (182,000) | 30,000 |
| Interest income | — | — | 2,578,000 | 300,000 |
| Interest income, net | 16,952,000 | 12,052,000 | — | — |
| Interest expense | (5,476,000) | (231,000) | — | — |
| Total other income (expense), net | 11,476,000 | 11,821,000 | 2,396,000 | 330,000 |
| Net Income | 20,890,000 | (175,850,000) | (38,988,000) | (24,067,000) |
| Other comprehensive income (loss) | ||||
| Net unrealized gain on marketable securities | 37,000 | 361,000 | — | — |
| Foreign currency translation adjustment | 17,000 | — | — | — |
| Total comprehensive income (loss) | 20,944,000 | (175,489,000) | — | — |
| Less: Undistributed earnings attributable to participating securities, basic | (415,000) | — | — | — |
| Less: Undistributed earnings attributable to participating securities, diluted | (415,000) | — | — | — |
| Net income (loss) attributable to common stockholders - basic | 20,475,000 | — | — | — |
| Net income (loss) attributable to common stockholders - diluted | 20,475,000 | — | — | — |
| Net income (loss) per share - basic | 0.4 | (4.38) | (2.36) | (2.87) |
| Net income (loss) per share - diluted | 0.39 | (4.38) | (2.36) | (2.87) |
| Weighted-average common shares outstanding - basic | 50,817,586 | 40,175,926 | 16,492,132 | 8,397,088 |
| Weighted-average common shares outstanding - diluted | 52,384,886 | 40,175,926 | 16,492,132 | 8,397,088 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.